We claim:

1. A sublingual formulation in the form of a lyophilized pharmaceutical composition that provides sublingual adsorption of riluzole comprising a pharmaceutically effective amount of riluzole or a pharmaceutically acceptable salt, solvate, anomer, enantiomer, hydrate or prodrug thereof, said formulation further comprising a tablet binder, a sugar alcohol selected from the group consisting of mannitol and sorbitol as a bulking agent, and docusate sodium as a solubilizing agent.

2. The sublingual formulation of claim 1 further comprising a flavoring agent.

3. The sublingual formulation of claim 1 further comprising a sweetener.

4. The sublingual formulation of claim 1 wherein the formulation riluzole comprises a riluzole prodrug.

5. The sublingual formulation of claim 3 said sweetener comprises sucralose.

6. A sublingual formulation comprising an effective amount of riluzole or a pharmaceutically acceptable salt, solvate, anomer, enantiomer, hydrate or prodrug thereof, said formulation further comprising a tablet binder, a bulking agent, and a solubilizing agent, said sublingual formulation providing an AUC at a dose of 35mg of from 110% to 180% of the AUC of an oral tablet formulation at a dose of 50mg, said AUC being measured at 0.5 hours, 1 hour or 2 hours after administration.

7. Use of the sublingual formulation of any of claims 1 to 6 in the manufacture of a medicament for the treatment of a neuropsychiatric disorder or symptom.

8. The use of claim 7 wherein the neuropsychiatric disorder is anxiety disorders, mood disorders, neurodegenerative disorders, pain disorders, ALS, cognitive disorders, Huntington's disease, Parkinson's disease, supranuclear palsy, frontotemporal dementia, frontotemporal lobar degeneration, delirium, Alzheimer's disease, mild cognitive impairment, mild cognitive impairment due to Alzheimer's disease, ataxia, hereditary ataxia, depression, mania, attention deficit disorders, drug addiction, dementia, agitation, apathy, anxiety, psychoses, post-traumatic stress disorders,

irritability, and disinhibition, learning disorders, memory loss, mental retardation, Rett Syndrome, tinnitus, personality disorders, bipolar disorders, obsessive-compulsive disorders, eating disorders, conduct disorders in DSM-5 and or combinations thereof.

9. The use of claim 7 wherein the neuropsychiatric symptom is anxiety, depression, stress, fatigue, feelings of panic, fear, uneasiness, problems in sleeping, cold or sweaty hands and/or feet, mood liability, mania, impaired concentration or attention, cognitive problems, obsessions, compulsions, repetitive behaviors, aggression, social phobias or impairments, stage fright, shortness of breath, heart palpitations, an inability to be still and calm, dry mouth, numbness or tingling in the hands or feet, nausea, muscle tension, dizziness apathy, elation, disinhibition, irritability, wandering, irritable bowel, belly pain, belly discomfort, diarrhea, change in bowel habits, abdominal bloating, abdominal gas, abdominal bloating, constipation or combinations thereof.

10. The use of claim 7 which produces a rapid therapeutic onset of action within about 10 minutes after administration.

11. The use of claim 7 which is associated with minimal or no oral numbness, or said oral numbness dissipates in less than 30 minutes.

12. The use of claim 7 wherein the liver function abnormalities side effects of riluzole are attenuated relative to those which are associated with the orally administered riluzole.

13. The use of claim 7 wherein the sublingual formulation is to be dosed at or below about 50 mg/day.

14. The use of claim 7 wherein the sublingual formulation is to be dosed at or below about 35 mg/day.

15. The use sublingual formulation of any of claims 1 to 6 in the manufacture of a medicament for the treatment of oral pain.

16. The use of claim 15 wherein a treatment area of oral pain is throughout an oral cavity including the upper surface of the tongue, lips, buccal area, back of throat, entire oral cavity or combinations thereof.

17. The use of claim 15 wherein the oral pain for treatment is caused by infection, inflammation, burn, cut, toothache, sore gums, canker sores, braces, minor dental procedures, denture irritation, oral surgery, neurologic disorders, disorders of the mucosa, oral ulcers, chemotherapy agents or combinations thereof.